Amgen subpoenaed on anemia treatments
Amgen Inc., the world’s largest biotechnology company, said Friday that it received a second subpoena from the U.S. attorney’s office in Washington state in connection with the company’s anemia drugs.
Amgen received the “supplemental” subpoena July 18 for documents regarding “the sales and marketing of our products, and our collection and dissemination of information” on the drugs’ efficacy and safety, the Thousand Oaks company said in a filing with the Securities and Exchange Commission.
The House Committee on Energy and Commerce, led by Rep. John D. Dingell (D-Mich.), said March 31 that it was asking Amgen for documents on its print and television advertising.
Last year, Amgen got subpoenas seeking information about its products from the U.S. attorney’s office in Seattle and from the U.S. attorney’s office for the Eastern District of New York, the company said in a Nov. 12 filing.
The view from Sacramento
Sign up for the California Politics newsletter to get exclusive analysis from our reporters.
You may occasionally receive promotional content from the Los Angeles Times.